Congenital aortic valve stenosis is a subgroup of congenital heart disease characterized by an obstruction of the left ventricular tract in which the lesion is located at the valvular level. The malformation affects approximately 0.04-0.38 per 1000 live births1.
The available options for the correction are many, each with its own advantages and disadvantages. For patients suitable for a biventricular correction2, the approach may be aimed at valve repair (percutaneous or surgical valvulotomy) or its replacement3. The latter is preferred when the aortic valve is considered unsalvageable; however, the available options are limited for pediatric patients. Indeed, bioprosthetic valves are not indicated for aortic replacement in the young population due to their early calcification4. On the other hand, degeneration in mechanical valves is considerably slower, but these require lifelong anticoagulant therapy5. In addition, the major limitation of these prostheses is represented by the lack of growth potential, which predisposes the patients to additional reinterventions.
An interesting therapeutic option in the pediatric population is the transfer of the pulmonary autograft to the aortic position named "Ross operation". In this case, the pulmonary valve is then replaced with a homograft (Figure 1)6. This procedure can possibly represent the best surgical choice for children because the pulmonary autograft preserves its growth potential and does not carry the risks of lifelong anticoagulant therapy. Furthermore, the Ross procedure can be of great value also in young adults to avoid a mechanical or biological valve, having the potential to become the best surgical solution.
Results after aortic valve replacement with pulmonary autograft are excellent, with survival greater than 98% and good long-term outcomes7. Literature studies report 93% and 90% freedom from replacing the pulmonary homograft at 4 and 12 years, respectively8.
The major limitation of this procedure is the tendency of the autograft to dilate in the long term, especially when employed as a freestanding root replacement. This can cause valvular incompetence which may require a reintervention. Indeed, the longest follow-up study performed so far reports freedom from reoperation for autograft replacement of 88% at 10 years and 75% at 20 years9.
The possibility of recreating a Ross operation in an experimental setting represents a fundamental prerequisite to investigate the underlying mechanism of the pulmonary autograft adaption to systemic pressures. Several models have been proposed in the past. However, these are usually limited to ex-vivo experiments or in-vivo animal models with a relatively expensive large animals. In this study, we sought to establish a rodent model of pulmonary artery graft (PAG) implantation in a systemic position, as freestanding root.